Skip to content
2000
Volume 8, Issue 12
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Recently, the serotonin 5-HT6 receptor has been identified as a drug target for attenuating cognitive deficits associated with Alzheimer's disease (AD). Additionally, this receptor may also play a role in schizophrenia, anxiety and obesity. Reports in the literature suggest that the production of selective antagonists for the 5-HT6 receptor has increased during the last 10 years, with some compounds currently in clinical trials for the treatment of AD. In this review, we will address the rationale for using 5-HT6 receptor antagonists in AD, as well as report on current advances in the understanding of the structure-activity relationships required to synthesize 5-HT6 receptor antagonists.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/156802608785161420
2008-08-01
2025-06-01
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/156802608785161420
Loading

  • Article Type:
    Research Article
Keyword(s): arylsulfonyl; dementia; G-coupled protein receptor; GCPR; multifunctional; QSAR; tryptamine
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test